New study tests smarter scans and blood tests for Hard-to-See breast cancer spread
NCT ID NCT07635654
First seen Jun 11, 2026 · Last updated Jun 20, 2026 · Updated 2 times
Summary
The DELILA study is testing whether whole-body MRI scans and ctDNA blood tests can better detect cancer spread in people with stage IV invasive lobular breast cancer (ILC), a type that often hides on standard scans. Researchers will enroll 43 patients starting first-line therapy and compare these new methods with usual imaging over 30 months. The goal is to see if these tools help doctors make earlier and more accurate treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC INVASIVE LOBULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could show that whole-body MRI and ctDNA blood tests are better at finding cancer spread in lobular breast cancer, leading to earlier treatment changes and more patients qualifying for clinical trials.
What could go wrong
This is a small, early-stage observational study (43 people) that is not yet recruiting. It aims to improve detection, not treat the cancer, so it won't directly change outcomes. The tests may not prove more useful than current methods.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.